高级检索
当前位置: 首页 > 详情页

Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China [2]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [3]Department of Urology, University of California, San Francisco, California [4]Research Institute, GloriousMed Clinical Laboratory Co., Ltd., Shanghai, China [5]West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China [6]Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
出处:
ISSN:

关键词: clinical outcomes genomics pediatric transcription features TFE3-RCC

摘要:
TFE3-rearranged renal cell carcinoma (TFE3-RCC) is a rare but aggressive subtype of kidney cancer that mainly affects young patients. However, the molecular characteristics of TFE3-RCCs in children and adolescents remain poorly understood. To this end, we performed a comprehensive study to characterize the genomic and transcriptional profiles of pediatric/adolescent TFE3-RCCs and compare them with those of adult tumors. In this study, 17 pediatric/adolescent patients with TFE3-RCC who underwent kidney surgery between 2009 and 2023 were selected from our multicenter TFE3-RCC database (n = 118). Whole-exome and RNA sequencing were performed on untreated primary tumor tissues. Detailed clinicopathological data and patient follow-up information were collected for analysis. ASPSCR1::TFE3 fusion was the most common fusion subtype in pediatric/adolescent patients. Tumors with ASPSCR1::TFE3 fusion developed at a younger age compared with those with other fusion subtypes (median age: 21 years vs 39 years, P < .001). Pediatric/adolescent TFE3-RCCs demonstrated similar genomic features and survival outcomes to those in adults. Similar to adult tumors, pediatric/adolescent TFE3-RCCs with ASPSCR1::TFE3 fusion displayed higher expression of angiogenesis, proliferation, and stroma gene signatures and responded favorably to anti-PD1 plus tyrosine kinase inhibitor combination therapy. This study provides comprehensive insights into the genomic and transcriptional features of pediatric/adolescent TFE3-RCCs, suggesting the importance of transcriptional signatures and the potential therapeutic strategies tailored for this population.Copyright © 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 病理学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 病理学
第一作者:
第一作者机构: [1]Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:56486 今日访问量:0 总访问量:4732 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号